Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The SLC6A3 gene possibly affects susceptibility to late-onset alcohol dependence but not specific personality traits in a Han Chinese population.

Huang CC, Kuo SC, Yeh YW, Chen CY, Yen CH, Liang CS, Ho PS, Lu RB, Huang SY.

PLoS One. 2017 Feb 9;12(2):e0171170. doi: 10.1371/journal.pone.0171170. eCollection 2017.

2.

Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Van Skike CE, Maggio SE, Reynolds AR, Casey EM, Bardo MT, Dwoskin LP, Prendergast MA, Nixon K.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:269-87. doi: 10.1016/j.pnpbp.2015.11.004. Epub 2015 Nov 12. Review.

3.

A review of 5-HT transporter linked promoter region (5-HTTLPR) polymorphism and associations with alcohol use problems and sexual risk behaviors.

Rubens M, Ramamoorthy V, Attonito J, Saxena A, Appunni S, Shehadeh N, Dévieux JG.

J Community Genet. 2016 Jan;7(1):1-10. doi: 10.1007/s12687-015-0253-1. Epub 2015 Sep 4.

4.

Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.

Thompson MD, Kenna GA.

Alcohol Alcohol. 2016 Mar;51(2):164-71. doi: 10.1093/alcalc/agv090. Epub 2015 Aug 26. Review.

5.

Serotonergic gene variation in substance use pharmacotherapy: a systematic review.

Bauer IE, Graham DP, Soares JC, Nielsen DA.

Pharmacogenomics. 2015;16(11):1307-14. doi: 10.2217/pgs.15.72. Epub 2015 Aug 12. Review.

6.

Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR.

Alcohol Clin Exp Res. 2015 Sep;39(9):1557-70. doi: 10.1111/acer.12800. Epub 2015 Aug 6. Review.

7.

Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis.

Falk DE, Castle IJ, Ryan M, Fertig J, Litten RZ.

J Addict Med. 2015 Jul-Aug;9(4):296-303. doi: 10.1097/ADM.0000000000000133.

8.

Treatment of co-occurring anxiety disorders and substance use disorders.

McHugh RK.

Harv Rev Psychiatry. 2015 Mar-Apr;23(2):99-111. doi: 10.1097/HRP.0000000000000058. Review.

9.

The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.

10.

Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.

Hien DA, Levin FR, Ruglass LM, López-Castro T, Papini S, Hu MC, Cohen LR, Herron A.

J Consult Clin Psychol. 2015 Apr;83(2):359-69. doi: 10.1037/a0038719. Epub 2015 Jan 26.

11.

A naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment.

Zorick T, Mandelkern MA, Brody AL.

J Clin Psychiatry. 2014 Dec;75(12):e1433-8. doi: 10.4088/JCP.14m09012.

12.

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol. 2014 Sep;48(6):515-22. doi: 10.1016/j.alcohol.2014.04.005. Epub 2014 Aug 14.

13.

5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men.

Chen AC, Davis CM, Kahler CW, Kuerbis AN, Covault J, Kranzler HR, Morgenstern J.

Alcohol Clin Exp Res. 2014 Sep;38(9):2362-8. doi: 10.1111/acer.12492. Epub 2014 Jul 28.

14.

Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol Clin Exp Res. 2014 Jun;38(6):1567-74. doi: 10.1111/acer.12410. Epub 2014 Apr 28.

15.

Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.

Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL.

Am J Addict. 2014 May-Jun;23(3):288-93. doi: 10.1111/j.1521-0391.2014.12102.x.

16.

Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

Wackernah RC, Minnick MJ, Clapp P.

Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014. Review.

17.

Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Haass-Koffler CL, Leggio L, Kenna GA.

CNS Drugs. 2014 Apr;28(4):343-60. doi: 10.1007/s40263-014-0149-3. Review.

18.

Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Zindel LR, Kranzler HR.

J Stud Alcohol Drugs Suppl. 2014;75 Suppl 17:79-88. Review.

19.

A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients.

Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, Lord S, Bisaga A, Aharonovich E, Levin F, McDowell D, Nunes EV.

Am J Addict. 2014 Jan-Feb;23(1):68-75. doi: 10.1111/j.1521-0391.2013.12065.x. Epub 2013 Jun 26.

20.

Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism.

Enoch MA.

Pharmacol Biochem Behav. 2014 Aug;123:17-24. doi: 10.1016/j.pbb.2013.11.001. Epub 2013 Nov 9. Review.

Supplemental Content

Support Center